Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study-Reference-Cited by-同舟云学术

Efficacy and safety of pioglitazone added to alogliptin in Japanese patients with type 2 diabetes mellitus: a multicentre, randomized, double-blind, parallel-group, comparative study

Published:2015-10-23 Issue:12 Volume:17 Page:1198-1201
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kaku K.¹,Katou M.²,Igeta M.²,Ohira T.²,Sano H.²

Affiliation:

1. Department of Medicine; Kawasaki Medical School; Okayama Japan

2. Takeda Development Center Japan, Takeda Pharmaceutical Company Limited; Osaka Japan

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12555/fullpdf

Reference12 articles.

1. Pathogenesis of type 2 diabetes mellitus;DeFronzo;Med Clin North Am,2004

2. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes;Tan;Diabetes Care,2005

3. Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004;Ford;Diabetes Care,2008

4. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report;Koro;Diabetes Care,2004

5. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006;Cheung;Am J Med,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action;ACS Medicinal Chemistry Letters;2022-11-02

2. Enterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota;Acta Biochimica et Biophysica Sinica;2022-10-01

3. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study;Diabetes & Metabolism Journal;2022-09-30

4. Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus;Drug Safety;2019-10-25

5. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development;International Journal of Molecular Sciences;2018-07-27